ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.

Clinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

THERAPEUTIC DRUG MONITORING, published by Lippincott Williams & Wilkins, is a prestigious journal that focuses on the critical area of pharmacology, with a specific emphasis on the therapeutic optimization of drug therapy. With an ISSN of 0163-4356 and an E-ISSN of 1536-3694, this peer-reviewed journal has been contributing valuable research and insights to the field since its inception in 1979. As of 2023, it holds a Q2 classification in the Pharmacology category, indicating its prominent role in advancing pharmaceutical sciences. The journal aims to enhance understanding of drug effectiveness and safety through rigorous studies on drug monitoring and individualized therapy, making it an essential resource for researchers, healthcare professionals, and students dedicated to improving patient care. With its solid standing reflected in Scopus rankings, including a rank of #103 in medical pharmacology and a 62nd percentile, THERAPEUTIC DRUG MONITORING continues to be a vital publication for those aiming to contribute to and stay informed about the latest developments in the field.

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.